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ABSTRACT	
  
IL-1β Amplification of Nitric Oxide Production and Its Inhibitory Effects on Glucose Induced
Early Growth Response-1 Expression in INS-1 Cells
	
  
by	
  
Ada	
  Young	
  
The pathophysiology of cytokines released by infiltrating white blood cells upon pancreatic beta
cells is not fully understood. Early growth response gene-1 (Egr-1) expression is specifically and
transiently up regulated in pancreatic beta cells in response to glucose. We hypothesized that
interleukin-1 beta (IL-1β) induction of nitric oxide alters glucose induced Egr-1 transcription
levels. Egr-1 levels were assessed via western blot, nitric oxide was measured with a Griess
Reagent kit and insulin levels via ELISA. Glucose induced both insulin and Egr-1 production in
INS-1 cells. IL-1β dose dependently increased nitric oxide production over time and
significantly attenuated glucose induced Egr-1 expression. Sodium nitroprusside dose
dependently reduced glucose induced Egr-1 production. The data suggest a strong relationship
between IL-1β induced nitric oxide production and the reduction of glucose stimulated Egr-1
production. The pathways altered by this cytokine could provide a better understanding of the
pathophysiology leading to pancreatic beta cell death.
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CHAPTER 1

INTRODUCTION

The pancreas is a glandular organ that is intricately involved in the gastrointestinal
digestive process. It regulates the uptake of carbohydrates, lipids, and proteins by releasing
insulin to bind to specific insulin responsive tissues (Boron and Boulpaep 2003). The major
targets of insulin include liver, muscle, and adipose tissue (Nussey and Whithead 2001). The
regulation of metabolism through the pancreas occurs via the binding of specific
neurotransmitters by the exocrine gland cells and glucose by the endocrine gland cells,
respectively (Boron and Boulpaep 2003). The endocrine portion of the pancreas contains beta
cells found within the islets of Langerhans. Increased blood glucose stimulates the pancreatic
beta cells to synthesize and secrete insulin into the blood stream (Boron and Boulpaep 2003).
Once in circulation, insulin binds to specific target tissues, making them more receptive to
glucose uptake (Nussey and Whithead 2001). Insulin also acts in an autocrine and paracrine
fashion, binding to the beta cells it is released from and/or adjacent beta cells (Boron and
Boulpaep 2003). It is the flux of islet beta cell binding to glucose and insulin that regulates
insulin production and secretion within the pancreas.

Receptors specific for glucose (ex. GLUT 2) can bind and passively transport the sugar
molecules into the cell depending upon the concentration gradient between the inside and the
outside of the cell. Once glucose enters the cell, a key enzyme, glucokinase, initiates the process
of glycolysis. This metabolic process affects production and secretion of insulin (Ashcroft 1980;
German 1993). Oxidative glucose metabolism increases ATP within the cell, closing ATP
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sensitive potassium channels leading to cellular depolarization via calcium influx (Figure 1.1).
The increased concentration of cytosolic calcium is a very important component in the glucosestimulated exocytosis of insulin granules (Szollosl et al. 2007). The breakdown of glucose for
energy and the influx of calcium alter the concentrations of a number of key regulatory enzymes
and in turn activate pathways that help promote insulin production and release and overall beta
cell health. It is critical to the health of the pancreas and the organism as a whole for these
pathways and molecules to interact in a balanced and consistent manner. A disruption or
imbalance can lead to beta cell dysfunction and even affect the use of glucose throughout the
body.

Figure 1.1 – Schematic model of glucose stimulated insulin production and exocytosis in a
healthy pancreatic β cell (Adapted from Gottlob et al. 2001; Srinivasan et al. 2002; Szollosl et al.
2007).
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Development of Insulin Dependent Diabetes Mellitus

Insulin-dependent diabetes mellitus (IDDM or Type 1 diabetes) is one of the most
frequent chronic childhood diseases with a prevalence estimated to affect approximately 120,000
individuals less than 19 years-of-age and 300,000 to 500,000 individuals of all ages (LaPorte et
al. 1995). The risk of devastating complications associated with this disease remain high and
include such things as heart disease, stroke, high blood pressure, blindness, kidney disease,
amputations, etc. Although great strides have been made towards understanding the pathogenesis
of IDDM, therapies for its prevention have remained elusive.
Insulin-dependent diabetes mellitus is a macrophage-dependent, T Cell-mediated
autoimmune disease characterized by the infiltration of the islet cells of the pancreas by immune
cells (insulitis) followed by massive destruction of insulin-producing pancreatic beta cells.
Mediation of islet beta cell destruction involves the participation of a variety of
immune/inflammatory cells in the insulitis lesion, notably dendritic cells, macrophages and T
lymphocytes, as well as cytokines produced by these cells (Thomas et al. 2000; Yoon and Jun.
2005; Lehuen et al. 2010). It is believed that the autoimmune response in IDDM involves some
disturbance(s) in the immunoregulatory balance that leads to a dominance of Th1 cells and their
respective cytokine production (Thivolet. 2002; La Torre et al. 2010; Lehuen et al. 2010).

Role of Macrophages and IL-12 Production in the Development of IDDM

A large body of evidence has been produced suggesting macrophages are a key part of
the initial steps in the development of IDDM (Lee et al. 1988; Yoon and Jun. 1999; Alleva et al.
2000; Lehuen et al. 2010). Much of this evidence has been obtained through the use of mouse
	
  

10	
  

and rat models. BioBreeding (BB) rats and nonobese diabetic (NOD) mice have been used
extensively in this area of research due to their spontaneous development of autoimmune type 1
diabetes. It has been found in both BB rats and in NOD mice that macrophages infiltrate the
pancreas during the initial phase of insulitis (Karges et al. 1995; Lehuen et al. 2010). The
recruitment of auto-reactive T-cells is dependent upon the activated macrophages and is
necessary for the development of the disease (Jun et al. 1999; Lehuen et al. 2010). The
pertinence of macrophages in the development of diabetes has been reproduced in a number of
other studies and is thought to be accomplished through cytokine signaling between the T-helper
cells (Th), macrophages, and beta cells (Karges et al. 1995; Jun et al. 1999; Thomas et al. 2000;
Yoon and Jun. 2005; Eizirik et al. 2009; Lehuen et al. 2010).
The balance of Th1/Th2 cell populations has been observed to be an important factor in
the development of immune dysfunction (Delovitch et al. 1997). The cytokine IL-12, released by
macrophages is understood to be a key regulator in the promotion of Th1 development and has
been found to be expressed at high levels in NOD mice macrophages (Alleva et al. 2000). Jun et
al. (1999) found that macrophage depleted NOD mice had lower IL-12 expression which
prevented diabetes from developing. When they added IL-12 back into the macrophage depleted
NOD mice, they found a drastic increase in diabetes development. IL-12 has not only been found
to stimulate Th1 activation but it has also been found to cause direct damage to beta cells
(Lehuen et al. 2010). Based on these and other findings, it appears that the essential role of
macrophages in the development of IDDM was due, in part, to their production of IL-12.
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Role of Immune Cell Cytokine Signaling in the Development of IDDM

A substantial amount of evidence from studies using BB rats and NOD mice supports a
critical role for T cells and macrophages in the development of IDDM (Rabinovitch and SuarezPinzon. 1998; Jun et al. 1999; Yoon et al. 2005; Leheun et al. 2010). Insulitis is characterized by
leukocyte infiltration of the pancreatic islets by a mixture of CD4+ and CD8+ lymphocytes, Blymphocytes, macrophages, and dendritic cells in NOD mice and humans recently diagnosed
with IDDM (Thomas et al. 2000; Yoon and Jun. 2005; Lehuen et al. 2010). As was previously
described, macrophage secretion of IL-12 directs T helper cells to differentiate along the Th1
pathway and stimulates the production of a variety of proinflammatory (IL-1ß and TNFα) and
Th1 cytokines (IL-2 and IFN-γ) (Jun et al. 1999; Alleva et al. 2000; Yoon and Jun. 2005). The
potential role of these proinflammatory and Th1 cytokines in the development of diabetes has
been the primary focus of numerous research studies over the past few decades (Jun et al. 1999;
Alleva et al. 2000; Thomas et al. 2000; Yoon and Jun. 2005; Lehuen et al. 2010).
Activation of CD4+T cells and CD8+T cells to pancreatic autoantigens is induced by the
binding of macrophages and dendritic cells and their consequential release of IL-12 (Yoon and
Jun. 2005). Macrophage activated Th1 cells release cytokines, including IL-2, which signal white
blood cells to migrate and respond to pancreatic beta cells (Rabinovitch and Suarez-Pinzon
1998). CD4+ T cells release IFNγ, acting in a cyclical fashion, inducing macrophages to become
cytotoxic (Yoon and Jun 2005). The combined release of IFNγ by T-cells and cytotoxic
macrophages activates other resting macrophages (Yoon et al. 1998). The large population of
cytotoxic macrophages and active dendritic cells then release a series of detrimental cytokines to
the beta cells including interleukin-1beta (IL-1β), Tumor Necrosis Factor (TNF), and free
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radicals (Uno et al. 2007). A number of studies have found IL-1β and TNF damage islet cells
and induce apoptosis (Thomas et al. 2000; Yoon and Jun. 2005; Uno et al. 2007; Schwarznau et
al. 2009).
Tumor Necrosis Factor is a cytokine mainly produced by macrophages and T-helper
cells. Green et al. (1998) found that the expression of TNFα in the beta cells of neonatal NOD
mice caused diabetes development in all mice. Kagi et al. (1999) produced a TNFR-1 deficient
NOD mouse model that developed insulitis but not diabetes. Studies have found TNFα
combined with IFNγ are very important factors in the destruction of beta cells and have often
been studied in congruence with a macrophage-derived cytokine, IL-1β (Campbell et al. 1988;
Suk et al. 2001; Wachlin et al. 2003; Kim et al. 2007). Cumulatively, these findings support the
involvement of many immune cells and their respective cytokines in the pathogenesis of IDDM.
They support the concept posed by Rabinovitch (1998) and many other researchers that the
deletion of a single “pathogenic” cytokine is not likely to be sufficient for complete prevention
of diabetes.
	
  
Interleukin 1-beta (IL-1β) Induces Nitric Oxide Production

The cytokine IL-1β is released by macrophages and pancreatic beta cells depending upon
the type of stress the cells are under (Maedler et al. 2002; Donath et al. 2010; Venieratos et al.
2010). Once bound to the cell, IL-1β in high doses activates pathways leading to cell dysfunction
and eventually to apoptosis. Nuclear factor kappa B (NfкB), a ubiquitous transcription activator,
is activated by glucose and IL-1ß. Activation of NF-ĸB via IL-1ß alters its role, inducing beta
cell apoptosis (Eldor et al. 2006; Ortis et al. 2008). The damage and eventual death of the beta

	
  

13	
  

cell is in part due to the activation of iNOS and production of the reactive oxygen species NO via
activation of NF-kB (Evans et al. 2003; Aktan 2004). Chen et al. (2000) found when selecting
for INS-1 cells resistant against IL-1β that the cells had a disruption in the NF-kB/iNOS
pathway. Eldor et al. (2006) found with the use of a transgenic mouse model expressing a
degradation resistant NFкB protein inhibitor that the effects of cytokine attack could be
prevented. The negative effect of IL-1β on healthy pancreatic beta cell pathways has been
reported to affect the PI3/Akt pathway as well (Aikin et al. 2004; Elghazi et al. 2006; Martinez et
al. 2006).
The enzyme Phosphoinositide 3-kinase and one of its main targets, protein kinase B
(Akt), are known to be directly affected by glucose and IL-1ß in beta cells (Elghazi et al. 2006;
Martinez et al. 2006). Increased expression of this kinase participates in beta cell survival
through inhibition of the JNK pathway, a stress responsive pathway (Aikin et al. 2004; Elghazi et
al. 2006). Aikin et al. (2004) also found inhibition of PI3K made beta cells more susceptible to
cytokine mediated death. The reduction of Akt/PKB activity has been shown to exhibit defective
insulin secretion but normal beta cell mass (Bernal-Mizrachi et al. 2004). When the islet cells are
bound by IL-1β, the JNK pathway is up regulated as are the reactive nitrogen species produced
by that pathway (Kang et al. 2009; Schwarznau et al. 2009). One of the more notorious and
detrimental effects of IL-1β and the pathways it alters is the up regulation of inducible nitric
oxide synthase (iNOS) and thus nitric oxide (NO) production, inhibiting mitochondrial glucose
oxidation (Ortis et al. 2008, Ortis et al. 2010).
The reactive nitrogen species produced by IL-1β are known to be a major inducer of
pancreatic beta cell apoptosis (Eckhardt et al. 1999; Eldor 2006; Friberg et al. 2010). The
enzyme iNOS, once up-regulated by this cytokine and related MAPKs, produces nitric oxide

	
  

14	
  

(NO) leading to beta cell dysfunction (Larsen et al. 1998; Eckhardt et al. 1999). Nitric oxide is so
detrimental because it reacts with prosthetic groups such as those found in transcription factors,
structures in DNA, and other proteins (Bogdan. 2001). Adaptability to nitric oxide imbalance
along with other causes of beta cell dysfunction has provoked the investigation of transcription
factors affected by cytokine and anti-oxidant pathways (Henderson et al. 1994; Kronke et al.
2011).

Role of Egr-1 in the Pancreatic Beta Cell

The effect of cytokines and other compounds on beta cells in IDDM directly influences
transcription factors and the products they create, including insulin. Early growth response 1
(Egr-1) is a ubiquitous, zinc-finger, transcription factor activated by many pathways and is
therefore involved in a number of disease states (Pagel & Deindl. 2011). The role of Egr-1 in
pancreatic beta cells has not been fully discerned. Based upon current research, it appears to have
a role in protecting beta cells and promoting cell viability in part through insulin production
(Josefsen et al. 1999; Eto et al. 2006; Kang et al. 2009; Chang et al. 2011).
Eto et al. (2006) found that varying levels of Egr-1 expression regulated insulin promoter
activity by controlling another transcription factor, PDX-1. Complimenting this study, Muller et
al, 2012 found that a doxycycline induced, Egr-1 double negative mouse model had significantly
decreased expression levels of PDX-1 and insulin mRNA compared to controls. Garnett et al.
(2005) silenced Egr-1 activity with small interfering RNA (siRNA) in INS-1 cells and also found
that glucose stimulation of insulin was not affected. Beta cell proliferation, however, was
inhibited in a glucose-independent manner. Recent studies focusing on anti-oxidant compounds
and beta cells have shown that Egr-1 is expressed and activates the transcription of γ	
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glutamylcysteine ligase (GCLC), a rate-limiting enzyme for glutathione (GSH) (Kang et al.
2009; Chang et al. 2011). Upregulation of GSH was found to protect the beta cell from NO
damage in INS-1 cells (Kang et al. 2009). These studies suggest Egr-1 plays an integral role in
the protection and health of pancreatic beta cells.
Proinflammatory cytokines released by immune cells drastically alter the pathways found
in normal, healthy pancreatic beta cells (Gurzov et al. 2008; Eizirik et al. 2009; Grunnet et al.
2009). The release of IL-1β by macrophages induces the JNK pathway eventually leading to the
upregulation of iNOS and NO production (Storling et al. 2005). Rabinovitch et al. (1996)
determined both IL-1β and IFNγ in part promote diabetes development through increasing iNOS
expression. Henderson et al. (1994) found increased levels of NO reduced Egr-1 expression
levels in rat lung macrophages. Kronke et al. (2001) further supported the Henderson et al.
(1994) observation. They treated Sp1 and Egr-1 with a NO donor, s-nitrosocysteine, and found
that it dose-dependently inhibited DNA binding. The increase of nitric oxide is just one of many
altered components when beta cells are affronted by cytokines (Figure 1.2). Glucose is a very
important component that binds beta cells and also has a strong effect on Egr-1 expression
(Figure 1.2).
	
  

Josefsen	
  et	
  al.	
  (1999)	
  found	
  that	
  glucose	
  dose	
  dependently	
  stimulated	
  Egr-‐1	
  

expression	
  strongly	
  in	
  glucose	
  responsive	
  cell	
  lines	
  MIN6,	
  INS-‐1,	
  and	
  βTC-‐3,	
  weakly	
  in	
  
RINm5F	
  cells,	
  and	
  not	
  at	
  all	
  in	
  HIT-‐T15	
  hamster	
  beta	
  cells.	
  Egr-1 is a transcription factor
regulated by its level of expression rather than by cellular location (Kang et al. 2007).	
  Induction
of Egr-1 via glucose appears to be regulated by calcium levels, c-AMP levels, ternary complex
factors, and kinases all induced by glucose binding (Frodin et al. 1995; Bernal-Mizrachi et al.
2001; Mayer et al. 2009). Mayer et al. (2009) determined Ca2+, PKC and activation ERK, a
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kinase, are integral to glucoses ability to upregulate Egr-1 expression. These studies and many
others suggest Egr-1 plays an important part in beta cell function that is yet to be fully
understood (Figure 1.2). Attaining a fundamental comprehension of how Egr-1 is affected by
positive and negative compounds binding the beta cell could lead to a more clear understanding
of how IDDM develops.

Figure 1.2 – Schematic model of pathways induced by IL-1β and Glucose affecting Egr-1.
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CHAPTER 2

PRETREATMENT OF INS-1 CELLS WITH IL-1B INHIBITS GLUCOSE-STIMULATED
EXPRESSION OF EGR-1.
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ABSTRACT

	
  
Objective: Inflammatory Early growth response gene-1 (Egr-1) expression is specifically and
transiently upregulated in pancreatic beta cells in response to glucose. It has been suggested that
genes transcriptionally regulated by Egr-1 may be important in normal beta cell function.
Recently, we reported that interleukin-1β (IL-1β) stimulates Egr-1 expression in pancreatic beta
cells and that co-administration of sodium nitroprusside, a nitric oxide donor, inhibits the IL-1βstimulated increase in Egr-1. The objective of this study was to determine if pre-treatment of beta
cells with IL-1β alters the ability of glucose to stimulate Egr-1 expression.
Research Design and Methods: Rat insulinoma cells (INS-1) were cultured for 24 hours in
glucose free RPMI 1640 media supplemented with fetal calf serum, L-glutamine, antibiotics,
sodium pyruvate and 2-β-mercaptoethanol (GFCM). In experiment 1, INS-1 cells were treated
with GFCM alone or GFCM supplemented with 20 mM glucose, 1 mM IBMX and 1 µM
forskolin and cultured for 0, 30, 60 and 120 minutes. After culture, media and cells were
collected and stored for subsequent determination of insulin levels and Egr-1 protein expression,
respectively. In experiment 2, cells were treated with GFCM alone or GFCM supplemented with
100 U/ml of IL-1β. After 24 hours, media was aspirated and replaced with GFCM alone or
GFCM supplemented with 20 mM glucose, 1 mM IBMX and 1 µM forskolin. After culture for 2
hours, cells were collected and stored for subsequent analysis of Egr-1 protein expression by
western blot.
Results: In experiment 1, administration of glucose significantly (P<0.05) increased insulin
levels at 60 (36.9 ng/ml) and 120 (51.6 ng/ml) minutes over that observed at time 0 (7.5 ng/ml).
Additionally, glucose treatment for 60 and 120 minutes significantly increased (P<0.05) Egr-1
protein expression in INS-1 cells as compared to those treated with GFCM alone. In experiment
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2, administration of glucose resulted in a 55 fold increase in Egr-1 protein expression as
compared to control levels. Pre-treatment with IL-1β completely inhibited (P<0.01) the glucosestimulated increase in Egr-1 protein expression.
Conclusions: Based on these results we speculate that IL-1β stimulation of nitric oxide and the
subsequent inhibition of glucose stimulated Egr-1 expression is detrimental to normal pancreatic
beta cell function.

	
  

20	
  

Introduction
Insulin-dependent diabetes mellitus (IDDM) is a macrophage-dependent, T cell-mediated
autoimmune disease characterized by the infiltration of the islet cells of the pancreas by immune
cells (insulitis) followed by massive destruction of insulin-producing pancreatic beta cells (Bach
1994). It is now generally accepted that pro-inflammatory and Th1 cytokines play a key role in
the destruction of the beta cells. Interleukin-1β (IL-1β) initiates a cascade of events that leads to
the activation of inducible nitric oxide synthase, the production of nitric oxide (NO) and the
subsequent destruction of the pancreatic beta cells by an apoptotic process (Corbet & McDaniel
1996; McDaniel et al. 1997). In addition, the administration of IL-1β inhibits glucose-stimulated
insulin secretion from rat islets (Hughes et al. 1990).
A major part of normal pancreatic beta cell function is the binding of glucose and the
subsequent stimulation of insulin production and secretion. In order to induce insulin
production, glucose must activate a series of transcription factors. Specifically, glucose has been
reported to induce the expression of early growth response gene (Egr-1) (Josefsen et al. 1999).
Changes in Egr-1 expression levels regulate other beta cell specific transcription factors
including the pancreas duodenum homeobox-1(PDX-1) and therefore insulin production (Eto et
al. 2006). The role of glucose stimulated Egr-1 expression and its effect upon insulin production
could play a very important part in understanding the development of IDDM.
During its development, a series of cytokines and chemokines are released by white
blood cells. Interleukin (IL) 1β is one of the cytokines released by macrophages in IDDM
development and is known to be a direct contributor to the induction of pancreatic β cell death.
It regulates a number of transcription factors including nuclear factor (NF)-кB and AP-1 (Cahill
and Rogers 2008; Liu and Khachigian. 2009). In human and rat aortic smooth muscle cells, IL-
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1β has been reported to stimulate histone 3 acetylation and phosphorylation at the Egr-1
promoter site (Wang et al. 2010). IL-1β activation of the inhibitor of DNA binding proteins is
directly mediated by Egr-1 binding in vascular smooth muscle cells (Zhu et al. 2007). IL-1β also
induces iNOS and thus nitric oxide production in rodent beta cells. In glomerular mesangial
cells, nitric oxide has been found to inhibit growth through impairing Egr-1 function (Rupprecht
et al. 2000). Further elucidation of the IL-1β and Egr-1 relationship could greatly benefit
understanding the process and thus the prevention of apoptosis in pancreatic β cells.
The role of glucose and IL-1β binding of the pancreatic β cell appear to affect each
other’s behavior in beta cells. Glucose metabolism is a normal part of beta cell function and is
generally believed to assist in the promotion of beta cell survival. IL-1β is a cytokine that
mediates abnormal beta cell function and generally assists in the progression of beta cell death.
Each of these molecules enacts similar pathways and both regulate Egr-1 expression. The role of
Egr-1during the development of IDDM, when both glucose and IL-1β are bound to the
pancreatic beta cell, is not fully understood. Herein, we demonstrate that IL-1β stimulated nitric
oxide production does inhibit glucose induced Egr-1 expression.
	
  
Research Design and Methods

Cell Culture

The rat insulinoma cell line INS-1 used in this work was obtained from Dr. Phillipe
Halban. Cells were grown in continuous culture in 175-cm2 flasks containing RPMI 1640
medium supplemented with 10% inactivated fetal calf serum, 2 ,mM L-glutamine, 1 mM
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pyruvate, 50 µM ß-mercaptoethanol, 100 I.U. penicillin, and 100µg/ml streptomycin penicillin
and streptomycin. Cells were cultured at 37°C in a humidified environment of 5% CO2 in air.

Sample Collection and Preparation

INS-1 cells were scraped and pipetted to detach from the wells and centrifuged at 3000
rpm for 5 minutes. The cell pellet was lysed by resuspending in 200 µl of lysis buffer (4% SDS,
50 mM Tris at pH6.8) and then boiled for 6 minutes. Protein concentration was determined by
the BCA (Sigma, St. Louis, MO) method with BSA as a standard. Samples were adjusted to
equal protein concentration by addition of lysis buffer. Glycerol (10%), BME (5%), and
bromophenol blue (0.025%) were added to each sample.

Western Blot

Forty µg total protein aliquots from each sample were loaded onto a 10% SDS-PAGE
(BioRad minigel) and run until the dye front reached the end of the gel. The gel was then blotted
to nitrocellulose for 1 hour at 100V in blotting buffer (25 mM Tris, 192 mM glycine, 20%
methanol) After blotting the nitrocellulose was dried at room temperature and then blocked
overnight in blotto (10 mM Tris pH 8.0, 150 mM NaCl, 0.05% Tween-20, 5% nonfat dry milk)
at 40C. The blot was then treated with rabbit polyclonal anti-Egr-1 (1:1,500, Santa Cruz, Santa
Cruz, CA) in blotto for 1 hour at room temperature. The blot was washed 6 times (5 min/wash)
in wash buffer (10 mM tris pH 8.0, 150 mM NaCl, 0.05% Tween-20). The blot was then
incubated with goat anti-rabbit IgG)-HRP second antibody 1:6,700, Santa Cruz, Santa Cruz, CA)
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for 1 hour at room temperature. The blot was then washed as previously described and reacted
with ECL (Amersham Pharmicia Biotech Inc., Piscataway, NJ) and exposed to Hyperfilm ECL
(Amersham Pharmicia Biotech Inc., Piscataway, NJ) for less than 10 minutes.

Measurement of Nitrite and insulin

Concentrations of nitrite, a stable metabolite of nitric oxide, in the culture media were
determined using a colorimetric procedure (Greiss Reagent). Insulin levels were determined
using a commercially available ELISA kit (Alpco, Windham, NH).

Experiment 1. Effect of Glucose on Insulin Production and Expression of Egr-1 in INS-1
Pancreatic Beta Cells

INS-1 cells were collected and plated (1 x 107 cells/well) in 6-well tissue culture plates
and cultured in 5 ml of media for 24 hours. Culture media was aspirated and replaced with
glucose free RPMI 1640 media (GFM) and cultured for an additonal 24 hours. Media was
aspirated and cells were cultured in GFM supplemented with 20 mmol/L glucose, 1 mM IBMX
and 1 µM Forskolin (GFM+) for 0, 30, 60, and 120 minutes respectively. After the appropriate
time, media from the sample was collected and stored at -70°C for subsequent determination of
insulin levels. Cells were collected and snap frozen for subsequent determination of Egr-1 levels
by western blot.
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Experiment 2. Effect of IL-1β Treatment on Nitric Oxide Production Over Time in INS-1 Cells.

INS-1 cells were collected, plated (2 x 105 cells/well) in 96-well tissue culture plates and
cultured in 200 µl of media. After 0, 3, 6, 12, 18, and 24 hours, media was aspirated and cells
were cultured in RPMI media alone or supplemented with 100 U/ml of IL-1β. After 0, 1, 2, 3, 6,
9, 12, and 24 hours cells were collected, processed, and stored at -70°C for subsequent
determination of Egr-1 protein expression by western blot.

Experiment 3. Effect of IL-1β Treatment Over Time on Glucose’s Ability to Induce Egr-1
Expression.

INS-1 cells were collected and plated (1 x 107 cells/well) in 6-well tissue culture plates
and cultured in 5 ml of media. After 24 hours, the media was aspirated and replaced with GFM
alone or GFM supplemented with 100 U/ml IL-1β at various times following media exchange (0,
6, 12, and 18 hours). Twenty four hours after the addition of GFM, media was aspirated and
replaced with GFM alone or GFM supplemented with 20 mmol/L glucose, 1 mM IBMX and 1
µM Forskolin. After 2 more hours cells were collected, processed, and stored at -70°C for
subsequent determination of Egr-1 protein expression by western blot.
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Experiment 4. Effect of Increasing Sodium Nitroprusside Concentrations on Glucose’s Ability to
Induce Egr-1 Expression.

INS-1 cells were collected and plated (1 x 107 cells/well) in 6-well tissue culture plates
and cultured in 5 ml of media. After 24 hours, media was aspirated and the cells were cultured in
GFM for an additional 24 hours. Media was aspirated again and cells were treated with GFM
alone, GFM supplemented with 20 mmol/L glucose, 1 mM IBMX and 1 µM Forskolin (GFM+),
or GFM+ containing various levels of sodium nitroprusside (1.25, 2.5, 5, and 10 mM). After 2
hours cells were collected, processed, and stored at -70°C for subsequent determination of Egr-1
protein expression by western blot.

Statistical Analyses

ANOVA and pair-wise contrasts were used to test differences among time point means.
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Results
Experiment 1.
Glucose stimulated insulin production in INS-1 cells. We examined the effect of glucose
on insulin production in the INS-1 pancreatic beta cells. INS-1 cells were treated with glucose
(20 mM) and cultured for 30, 60, and 120 minutes. The administration of glucose to the INS-1
cells significantly (P<0.05) increased insulin levels at 60 (36.9 ng/ml) and 120 (51.6 ng/ml)
minutes over that observed at time 0 (7.5 ng/ml) (Figure 2.1).
	
  

	
  
Figure 2.1: Glucose significantly stimulated insulin production from INS-1 cells cultured in
vitro at 60 and 120 minutes. Data are expressed as mean ± SEM of 3 experiments.
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Experiment 2.
Glucose increased expression of Egr-1 in INS-1 cells. We examined the effect of glucose
on the expression of Egr-1 in INS-1 pancreatic beta cells. INS-1 cells were treated with glucose
(20 mM) and cultured for 30, 60, and 120 minutes. Treatment of the INS-1 cells with glucose
significantly (P<0.05) increased the expression of Egr-1 at 60 and 120 minutes of culture as
compared to the 0-hour time group (Figure 2.2).
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Figure 2.2: Effect of glucose on the expression of Egr-1 over time. Data are normalized to the
0-minute time period which was set at 1.0. Data are expressed as mean ± SEM of 3
experiments.
Experiment 3.
Interleukin-1ß dose-dependently increases nitric oxide in INS-1 cells. We examined the
effect of IL-1ß (0, 1, 5, 50, and 100 U/ml) on nitrite production in INS-1 pancreatic beta cells
over time (0, 3, 6, 12, 18, and 24 hours). Administration of IL-1ß dose-dependently increased
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nitrite production over time in the INS-1 pancreatic beta cells (Figure 2.3.). The figure also
shows that the administration of 50 and 100 U/ml of IL-1ß increased nitrite production from
INS-1 cells after 6 hours of culture and continued to further increase nitrite levels through 24
hours of culture. These data show a direct relationship between IL-1β and Nitric oxide
production. The time lag of six hours indicates the possibility of several intermediates in the
pathway between IL-1β stimulation and NO production in the INS-1 pancreatic beta cells.
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Figure 2.3: Administration of IL-1β (U/ml) dose-dependently increased nitric oxide production
from INS-1 cells cultured in vitro for 0, 3, 6, 12, 18, and 24 hours. Data are expressed as a mean
for each of the three experiments.
Experiment 4.
Pre-treatment of INS-1 cells with IL-1ß attenuates the glucose-stimulated increase in
Egr-1 protein expression in a time dependent manner. We examined the effect of glucose on
Egr-1 expression in INS-1 pancreatic beta cells that had been previously treated with IL-1ß. Pre-
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treatment of INS-1 cells with IL-1ß (100 U/ml) inhibited the glucose-induced increase in Egr-1
protein expression in INS-1 cells cultured in vitro in a time dependent manner (Figure 2.4).
Specifically, treatment of INS-1 cells with IL-1β for 24, 18, and 12 hours before the
administration of glucose, significantly (p<0.05) attenuated glucose-stimulated expression of
Egr-1 by 24, 51, and 62 percent, respectively (Figure 2.4). In contrast, pre-treatment of INS-1
cells with IL-1β for 6 hours before the administration of glucose did not alter glucose-stimulated
expression of Egr-1 significantly (Figure 2.4). This is possibly because only after 6 hours was a
high amount of nitric oxide stimulation from IL-1β treatment of the INS-1 cells seen (Figure
2.3).
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Figure 2.4: Pre-treatment of INS-1 cells with IL-1ß attenuated the glucose-stimulated
increase in Egr-1 expression in a time dependent manner. Data are normalized to the glucose
treatment group which was set at 100%. Data are expressed as mean ± SEM for 3 experiments
Experiment 5.
Sodium Nitroprusside attenuates glucose-stimulation of Egr-1 expression in INS-1 cells.
To further verify the hypothesis that IL-1ß alters glucose-stimulated expression of Egr-1 in INS1 cells via the upregulation of nitric oxide, we examined the effect of sodium nitroprusside, a
nitric oxide donor, on glucose-stimulated expression of Egr-1 in INS-1 pancreatic beta cells.
INS-1 cells were treated with glucose (20 mM) alone or in the presence of increasing
concentrations of sodium nitroprusside (0, 1.25, 2,5, 5, and 10 mM) for 2 hours. Glucose
significantly (p<0.05) increased the expression of Egr-1 in INS-1 pancreatic beta cells cultured
for 2 hours (Figure 2.4). Co-administration of sodium nitroprusside, dose-dependently, inhibited
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the glucose-stimulated (P<0.05) increase in Egr-1 protein expression by INS-1 pancreatic beta
cells cultured in vitro for 2 hours (Figure 2.5). Administration of 2.5, 5, and 10 mM of sodium
nitroprusside decreased the glucose-stimulated increase (P<0.05) of Egr-1 protein expression by
15, 52, and 66 percent, respectively (Figure 2.5).

	
  
Figure 2.5: Administration of sodium nitroprusside dose-dependently inhibited glucose
stimulation of Egr-1 expression from INS-1 cells cultured in vitro for 2 hours. Data are
normalized to the glucose treatment group which was set at 100%. Data are expressed as mean ±
SEM for 3 experiments.
Based on these findings we conclude that nitric oxide is an important negative regulatory
intermediate of stimulated Egr-1 protein expression in INS-1 pancreatic beta cells. Our findings
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support our hypothesis that exposure of pancreatic beta cells to IL-1β initiates a cascade of
events that subsequently alters the ability of glucose to promote normal beta cell function.
Furthermore, our findings suggest that IL-ß’s ability to alter glucose stimulation of Egr-1 protein
expression involves the production of nitric oxide.
Discussion
Our long-range goal is to understand the pathophysiology of IDDM and to develop new
therapeutic strategies for prevention and/or treatment of this disease. In these studies we
investigated the role of nitric oxide to alter the glucose-stimulated increase in the expression of
the transcription factor, Egr-1. The importance of Egr-1 in normal beta cell function has been
emphasized by previous reports of its role in insulin mRNA expression and its paralleled
increase with insulin production in insulinoma cells (Frodin et al. 1995; Josefsen et al. 1999;
Bernal-Mizrachi et al. 2001; Eto et al. 2006; Muller et al. 2012). Our observation that glucose
stimulates the production of insulin and increases the expression of Egr-1 from cultured INS-1
pancreatic beta cells further supports those studies. Recently, Muller et al. (2012) concluded that
Egr proteins are import regulators of pancreatic beta cell function, influencing insulin
biosynthesis and glucose homeostasis.
Proinflammatory cytokines, such as IL-1ß and IFN-γ released by infiltrating immune
cells are thought to be key mediators of apoptosis in pancreatic beta cells (Rabinovitch and
Suarez-Pinzon 1998; Eizirik et al. 2001; Grunnet et al. 2009). Administration of IL-1ß alone, or
in combination with IFN-γ has been shown to induce markers of apoptosis and cell death in INS1 cells and rat and human islets (Grunnet et al. 2009; Wu et al. 2012). Administration of IL-1ß to
INS-1 cells significantly increased caspase-3 activity, a specific marker for apoptosis, by 7.6 fold
over that observed in INS-1 cells cultured in media alone (Wu et al. 2012). Furthermore, Wu and
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coworkers found that treatment of INS-1 cells with IL-1ß increased cell death by 49% over
untreated INS-1 cells.
Neutralization of IL-1ß by the administration of anti-IL-1ß antibody reduced the
incidence of cyclophosphamide-induced diabetes (34%) in non-obese diabetic (NOD) mice as
compared to controls (100%) (Cailleau et al.1997). Similarly, administration of 0.2 mg/kg and 2
mg/kg of a soluble IL-1 receptor to cyclophosphamide-treated NOD mice decreased the
incidence of diabetes (53% and 7%, respectively) as compared to controls (65%). Neutralization
of IL-1 did not alter insulitis to a great degree. These findings are consistent with the concept that
IL-1ß is integral to the process leading to IDDM and that it likely participates in the effector
phase because neutralization has little affect on insulitis (Rabinovitch and Suarez-Pinzon 1998).
Collectively these findings demonstrate that proinflammatory cytokines, in particular IL-1ß,
activate a series of events that ultimately lead to destruction of the pancreatic beta cells and onset
of IDDM. However, the exact mechanisms activated by the release of proinflammatory cytokines
in the pancreas, which lead to cell death, and IDDM remain to be determined.
A detrimental compound induced by IL-1β that, in part, leads the endocrine pancreas to
cell death and IDDM is nitric oxide (NO). Treatment of pancreatic beta cells with IL-1β has been
shown to increase inducible nitric oxide synthase (iNOS) and thus NO concentrations (Corbett et
al. 1991; Rabinovitch et al. 1996; Aktan 2004; Storling et al. 2005). In our studies,
administration of IL-1ß increased nitric oxide production over time in a dose dependent manner.
The role of nitric oxide as a key mediator of proinflammatory cytokine-induced beta cell death is
further supported by ablation/replacement studies using pharmacological inhibitors or donors of
nitric oxide production (Storling et al. 2005). Rat insulinoma cells, INS-1, incubated for 24
hours with IL-1β, IFNγ and then treated with NOS blocker NMA had a 90% reduction in
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apoptosis (Storling et al. 2005). When a nitric oxide donor SNAP was introduced into the culture
media of the same INS-1 cells over a 24-hour period, it dose-dependently induced apoptosis
(Storling et al. 2005). Kacheva et al. (2011) found similar results when treating INS-1E cells
with an iNOS blocker. They studied the NF-κB- iNOS pathway and found an iNOS blocker
inhibited IL-1β induced NF-κB activation. The detrimental effect of IL-1β induced NO on the
viability of pancreatic beta cells is suggested by these studies.
The increased concentration of NO due to IL-1β may be causing beta cell dysfunction
through altering transcription factor function. Transcription factors play a pivotal role in
producing and regulating products necessary for pancreatic beta cells to function properly. They
are strongly affected by the type of compound binding the cell whether it is glucose or proinflammatory cytokines, such as IL-1β. The importance of Egr-1 in pancreatic beta cell health
and function is supported in a number of studies (Frodin et al. 1995; Josefsen et al. 1999; BernalMizrachi et al. 2000; Garnett et al. 2005; Eto et al. 2006; Muller et al. 2012). It participates in
these positive functions through glucose stimulation (Josefsen et al. 1999; Eto et al. 2006; Muller
et al. 2012). NO production inhibits normal pathways enacted by glucose including insulin
secretion (Corbett et al. 1993; Tsuura et al. 1998; Henningsson et al. 2002). Henningsson et al.
(2002) treated mouse islets with 20mM of glucose for 60 minutes and found exogenous or
endogenous NO donors suppressed insulin secretion but increased it dramatically with nitric
oxide inhibitors. One target of NO in the glucose pathway that has been identified is
phosphofruktokinase (Tsuura et al. 1998). Another target of NO is the zinc finger transcription
factor Egr-1 (Henderson et al. 1994; Kroncke et al. 2001). Interference of glucose stimulated
Egr-1 via IL-1β induced NO production could play an important part in IDDM development.
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A number of studies using pharmacological donors of NO, including the present study,
suggests NO plays an important role in IDDM development through Egr-1. We found sodium
nitroprusside, a NO donor, dose dependently inhibited glucose induced Egr-1 production.
Henderson et al. (1994) treated rat lung macrophages with low doses of NO donor SNAP (0.11mM), before treatment with IFN and LPS and found a decrease in Egr-1 transcription by 70%.
A study treating glomerular mesangial cells (MC) with S-nitrosoglutathione (GSNO) suppressed
Egr-1 binding sites and ultimately inhibited MC proliferation (-84%) (Rupprecht et al. 2000).
Kroncke et al. (2001) found treatment of recombinant Egr-1 with NO donor S-nitrosocysteine
(SNOC) dose-dependently inhibited DNA binding by the transcription factor.
The role of IL-1β induced NO in pancreatic beta cell death is not fully understood. It is
widely recognized as playing a large part in beta cell destruction. Our studies confirmed that IL1β increased NO levels beginning at the 6-hour marker. This time frame coordinated with the
time it took for IL-1β to begin inhibiting glucose induced Egr-1 production. These 2 studies
show that IL-1β interferes with glucose’s ability to function normally in part through inhibition
of Egr-1. In order to confirm that it was nitric oxide and not another compound, we treated the
INS-1 cells with increasing concentrations of SNP and found Egr-1 was inhibited dosedependently. This reconfirms previous studies suggesting NO directly affects Egr-1 expression.
Our study has shown that IL-1β alters glucose’s ability to induce Egr-1 production through NO.
Our findings provide evidence for the first time that the increase in nitric oxide in pancreatic beta
cells during the onset of IDDM may alter the ability of glucose to promote cell viability and
inhibit insulin production, therefore leaving the cells more susceptible to cell death. 	
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APPENDICES
APPENDIX A
Cell Processing
Cell	
  Lysis	
  Buffer	
  
10%	
  SDS	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  	
  	
  4ml	
  

	
  

1M	
  Tris-‐HCL,	
  6.8pH	
   	
  

	
  

	
  

	
  

	
  

	
  

500µl	
  

	
  

diH2O	
   	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

5.5ml	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  10ml	
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APPENDIX B
Protein Assay
	
  
Diluted	
  Albumin(BSA)	
  Standards:	
  Thermo	
  Scientific	
  BCATM	
  Protein	
  Assay	
  Kit	
  
Vial	
  

Volume	
  of	
  Diluent	
  

Volume	
  &	
  Sourcoe	
  of	
  BSA	
   Final	
  BSA	
  Concentration	
  

A	
  

0µl	
  

300µl	
  of	
  stock	
  

2000µg/ml	
  

B	
  

125µl	
  

375µl	
  of	
  stock	
  

1500µg/ml	
  

C	
  

325µl	
  

325µl	
  of	
  stock	
  

1000µg/ml	
  

D	
  

175µl	
  

175µl	
  of	
  vial	
  B	
  dilution	
  

750µg/ml	
  

E	
  

325µl	
  

325µl	
  of	
  vial	
  C	
  dilution	
  

500µg/ml	
  

F	
  

325µl	
  

325µl	
  of	
  vial	
  E	
  dilution	
  

250µg/ml	
  

G	
  

325µl	
  

325µl	
  of	
  vial	
  F	
  dilution	
  

125µg/ml	
  

H	
  

400µl	
  

100µl	
  of	
  vial	
  G	
  dilution	
  

25µg/ml	
  

I	
  

400µl	
  

0	
  

0µg/ml=Blank	
  

	
  
	
  

	
  

	
  

	
  

	
  

	
  

	
  

	
  

BCA	
  Working	
  Reagent:	
  
	
  

	
  

BCA	
  Reagent	
  A	
  (50	
  parts)	
  +	
  Reagent	
  B	
  (1	
  part)	
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